Currently, there is a wide range of commercially available endografts for infrarenal abdominal aortic aneurysm (AAA) repair. Results of long-term follow up after endovascular aneurysm repair (EVAR) are limited. Thereby, the durability of these endografts and the difference between manufacturers is not fully clear.
Introduction
Since Parodi et al. 1 reported the concept of endovascular aneurysm repair (EVAR) in 1991, EVAR increasingly became the preferred option for treatment of abdominal aortic aneurysm (AAA). Currently, nearly 80% of all AAAs are treated by EVAR in the United States. 2, 3 EVAR is associated with a lower perioperative mortality and morbidity and a shorter hospital stay compared to open aneurysm repair (OAR). [4] [5] [6] However, long-term survival rates seem to be better for OAR, this is mainly attributed to secondary AAA rupture. 7 Furthermore, EVAR has been associated with a higher rate of secondary interventions and a significantly higher in-hospital cost of care compared to OAR. [8] [9] [10] Over time, technological advances have improved the capacity of endografts to treat aortic AAAs. Improved fabrics, better scaffolding designs and materials, low-profile delivery systems, more precise deployment mechanisms, enhanced fixation, greater conformability, and diverse modular components were developed and applied to newer generation endografts. 11 Most manufacturers of EVAR devices now produce their third-generation commercially available endograft. 12 These technological improvements, combined with increased surgical experience and selection of patients within the specified instructions for use (IFU), led to higher reintervention-free survival and higher freedom from aneurysm-related death after EVAR. 11, 13 Results of long-term follow up after EVAR are limited and the durability of endografts remains unclear. In this review, we describe mid-and long-term results of the latest-generation endografts currently commercially available for treatment of infrarenal AAAs. Primary outcome parameters were overall survival, freedom from AAA-rupture, and AAA-related death, while a secondary outcome measure was freedom from reintervention.
Materials and methods
A PubMed search was performed with Medical Subject Headings (MeSH) terms including "Aortic Aneurysm, Abdominal/surgery" combined with "Aortic Aneurysm, Abdominal/ therapy" or "abdominal aneurysm" and "endovascular procedures" or endovascular", "EVAR" and "follow-up". All 1519 articles published in the English literature over a 10-year period (until January 2018) were screened for title and abstract. Additional searches were done adding for terms of the specific endografts and by cross-referencing. Reports of results of elective EVAR performed within the IFU, and with a currently available endograft, were eligible for inclusion. Studies with a minimum median follow up of 36 months were eligible for comparative analysis between endografts. If early results of the endograft were published previously, relevant data were obtained from that earlier report.
To review the applicability of the different endografts, primary and secondary outcome measures were compared according to the reporting standards of Chaikof et al. Primary technical success requires a successful introduction and deployment of the device in the absence of surgical conversion, mortality, type I or III endoleaks, or graft limb obstruction. It can include the use of planned additional modular components, angioplasty, and adjunctive surgical procedures. If unplanned endovascular procedures are necessitated, the term assisted primary technical success is used. 14 Pooled analysis was done for primary and primary-assisted technical success, freedom from reintervention, overall-survival, freedom from AAArupture, and AAA-related death. Kaplan-Meier analysis was used for survival analysis, but when not available, survival or freedom from events at median follow up was presented. Separately, adverse events during median follow up were collected, including endograft patency, limb occlusion, endograft migration, kinking, stentbody fracture, disconnection, endoleak, and freedom from reintervention. In most selected articles, conversion from EVAR to open surgical repair was reported as early (<30 days) or late (>30 days) conversion. 14
Results
The inclusion criteria were met in 122 studies. Mid-and long-term results with a minimum median follow up of 36 
Zenith® Flex® AAA Endovascular Graft
The Cook Zenith® Flex® endograft is a three-part system consisting of a bifurcated aortic main-body and two iliac extensions (Figure 1a Table I . Long-term results of EVAR with Zenith® Flex® were reported in six papers. 12, [15] [16] [17] [18] [19] Figure 1a: The Cook Zenith® Flex® endograft.
30-day postoperative outcome
Only a few studies reported numbers for primary technical success (Table II ). In the study by Greenberg et al., three of the 739 implantations of the Zenith® Flex® AAA endograft were aborted due to iliac artery morphology not appreciated before the procedure of which two were successfully treated by open repair and the third patient decided to have no further intervention. 15 Thirty-day mortality was 1-3%, mostly non-AAA-related. In the report by Verzini et al., one of five perioperative deaths was due to AAA rupture. 12 Freedom from reintervention at 30 days was 93.4%. 15, 19 
Mid-and long-term outcomes
Overall survival in all six papers was estimated by Kaplan-Meier analysis (Table II) . Pooled analysis estimated an overall survival at eight years of 51.8%. 12, 18, 19 found an estimated overall survival of 37.8%, freedom from AAA rupture of 98.1%, freedom from AAA-related death of 97.3%, and freedom from late reintervention and conversion of 75.5%. 12 Adverse events related to EVAR during follow up are listed in Table IV .
The INCRAFT® AAA Stent Graft is a three-piece modular bifurcated system (Figure 2a patients. [20] [21] [22] The IFU during the INNOVATION trial are shown in Table I .
30-day postoperative outcome
Primary technical success was 90%. At the end of the procedure, 55 of 60 patients (92%) had absence of type I or III endoleak. One patient required a proximal aortic cuff for correction of a type Ia endoleak intraoperatively. Mortality at 30 days was 0% and freedom from reintervention at 30 days was 100%.
Mid-and long-term outcomes
Overall survival at one and two year follow up is shown in Table II 
Gore® EXCLUDER® AAA Endoprosthesis
The Gore® EXCLUDER® is Table I . The results of the Gore® EXCLUDER®, with a median follow up over 36 months, were described in three papers.
30-day postoperative outcome
Pooled analysis shows a primary technical success of 95.9%. [23] [24] [25] [26] In the series described by Bos et al., two patients had a type Ia endoleak at completion angiography. One was successfully corrected with a proximal extension. In the second patient, a small proximal endoleak was accepted after ballooning in a 50mm long neck and it spontaneously resolved at one-month follow up. 25 
Mid-and long-term outcomes
Overall survival is shown in Table II . 24 
The Endurant™ Stent graft
The Endurant™ II consists of a three-piece modular system with M-shaped nitinol stents secured to high density polyester (Figure 4a and b). Suprarenal fixation hooks were designed to compensate for the decreased columnar strength. The second-generation device (Endurant™ II stent graft) was improved with a lower-profile delivery system and longer limb lengths to accommodate a wider range of anatomical variations. Better delivery system visualization was accomplished by adding radio opaque markers to the endograft. IFU are shown in Table   I . Mid-and long-term results of the Medtronic Endurant™ were reported in six articles with a minimum median follow up of 36 months. [27] [28] [29] [30] [31] [32] Out of 897 patients included in the articles, 99 patients were treated outside the IFU.
30-day postoperative outcome
Pooled primary and primary-assisted technical success were 96.3% and 99.2%, respectively.
Two additional stent placements in a renal artery were required and one unplanned aorto-iliac device was placed. There were no primary type I or III endoleaks or conversions. 27, 33 The device could not be implanted in one patient due to stenotic iliac vessels, and the procedure was terminated. 28 The single technical device failure in the series described by Singh et al.
was due to an inability to cannulate a contralateral gate that was collapsed in a narrowed distal aorta and, essentially, this created a monoiliac device which was completed by a femoro-femoral crossover bypass. 30 In addition to procedures to resolve endoleaks, 
Mid-and long-term outcomes
Reported overall survival is shown in Table II . survival rates for those treated outside IFU. 27 patients. 28 One death was AAA related. In Oliveira et al. 's report, late AAA rupture occurred in two patients (3.1%), and this resulted in the death of one patient. 29 Freedom from reintervention and the main reasons for reinterventions are mentioned in Tables III and IV .
The Anaconda™ AAA stent graft system
The Anaconda™ is a three-piece modular graft system (Figure 5a 
Mid-and long-term outcomes
In the report of Freyrie et al., a follow up of 36 months was achieved in 14 patients in GA and in 120 patients in GB. 35 Overall survival at three years showed no statistically signifi cant diff erence in survival between treatment of angulated versus non-angulated necks ( Dias 16 Forbes 17 Mertens 18 Väärämäki 19 Verzini 12 Cordis Corp INCRAFT® Pratesi [20] [21] [22] GORE® EXCLUDER® Bos 25 Bastos Goncalves 26 Pratesi 23, 24 Medtronic Endurant™ Zandvoort 27, 33 Bisdas 28 Oliveira 29, 49 Singh 30, 50 Mannetje 31 Deery 32 Vascutek Anaconda™ Rödel 34 Freyrie 35 (GA≥60˚)
Freyrie 35 (GB<45˚) Dias 16 Forbes 17 Mertens 18 Väärämäki 19 Verzini 13 Cordis Corp INCRAFT® Pratesi [20] [21] [22] GORE® EXCLUDER® Bos 25 Bastos Goncalves 26 Pratesi 23, 24 Medtronic Endurant™ Zandvoort 27, 33 Bisdas 28 Oliveira 29, 49 Singh 30, 50 t Mannetje 31 Deery 32 Vascutek Anaconda™ Rödel 34 Freyrie 35 (GA≥60˚)
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Discussion
This review describes the results of the latest generation of currently available endografts for EVAR after a mid-and long-term outcome of 36 months of follow up.
The latest generation endografts are more flexible and low-profile. 36 There have also been improvements for more controlled deployment and easier catheterization. 37 The IFU are different for every specific type of endografts and help the clinician to choose the best available endograft for the treatment of a patient with an infrarenal AAA.
The current analysis showed comparable results between the endografts. The perioperative mortality, early reintervention, and early conversion rates were very low in all studied endografts, while the primary-assisted technical success varied between 83% and 100%. The latter appears to be lower in the Anaconda™ graft, potentially related to a higher incidence of type Ia endoleaks due to the stent design that needs more time to fully expand. Adhering to the IFU has led to good mid-and long-term clinical outcomes in all endografts. At three-year follow up, the freedom from AAA rupture and AAA-related death varied between 98% and 100%. The results, however, still demonstrate a significant complication and reintervention rate after EVAR, mainly occurring during the first three years after initial treatment.
Although newer generation endografts are used, this reintervention rate of 10-20% indicated the ongoing need for long-term follow up. [38] [39] [40] Long-term results of follow up of the current endografts with the newest adjustments are still awaited. Because the design and delivery system of the Zenith® Flex®, Gore® EXCLUDER®, Not included in this review are the results of The Global Registry for Endovascular Aortic Treatment (GREAT). This is a prospective observational multicenter cohort registry that enrolled 3166 patients receiving a Gore® EXCLUDER® endograft for treatment of an infrarenal AAA from January 2011 to January 2017. 46 The five-year follow-up results were only published in May 2018, which was outside the searching criteria for selecting studies for this review.
Howard et al. reported a technical success in 99.9% of cases. Freedom from reintervention was 93.7% at one year and 83.2% at five years. Five-year survival was 64.4% in the group with a large proximal aortic neck (≥25mm) and 76.5% in the group with a normal baseline proximal aortic neck (<25mm). 47 In 2012, the FDA approved the Medtronic Endurant™ II. Compared to the older Medtronic Endurant™ I design, it includes a lower-profile delivery system, longer limb lengths, and better delivery system visualization. No longterm follow-up study has been published yet, but good short-term results seem to reflect the changes in design.
Comparing the results of the INCRAFT® and Vascutek Anaconda™ with the other endografts is difficult because of the few published studies with a median follow up over 36 months.
During the first years, there was a tendency to perform EVAR in higher risk patients.
Although, for this study, only articles were selected that were published in the past 10 years, and they likely included higher risk cases which may have led to selection bias. 48 Most (15/18) 2 studies are prospective nonrandomized controlled design studies or retrospective analyses of prospective databases. Each clinician has its own preferences and experience, consequently influencing the choice to use a specific endograft. When interpreting outcomes from retrospective data, this selection bias might influence the results. When strictly adhering to IFU, this bias can be minimized, but a randomized control trial with long-term follow up would show the true difference between available endografts for infrarenal AAA repair.
Conclusion
Currently, there is a wide range of commercially available endografts for infrarenal abdominal aortic AAA repair. The long-term results of these devices are not fully clear but have possibly improved with the introduction of newer generation endografts for infrarenal AAA repair.
Nevertheless, given the differences in stent and graft design, each endograft will need to prove its own long-term efficacy. This review provides an overview of long-term results and the implications of choosing one of these latest generation endografts.
